Why does the oral formulation make this more important?

It depends on the SNAC absorption enhancer and strict administration conditions, so it is more sensitive to anything affecting gastric conditions.

Does diabetes status change the weight result?

Yes. Weight response has consistently been smaller in people with type 2 diabetes across this drug class.

GLP-1 & Incretin Science

Why Population-Specific Trials Are Run

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

OASIS 2 was a randomised clinical trial of oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes, published by Kadowaki and colleagues in JAMA Internal Medicine in October 2025.

Key facts

Trial: OASIS 2
Compound: Oral semaglutide
Population: East Asian, overweight or obesity
With or without: Type 2 diabetes
Published: JAMA Intern Med, 1 October 2025
PMID: 40758358

Why population-specific trials exist

Not as a formality. Body composition at a given body mass index differs between populations, and the BMI thresholds defining overweight and obesity are set lower in several East Asian countries because metabolic risk appears at lower BMI. A trial recruiting to different thresholds is studying a different population, not the same one relabelled.

What differs pharmacologically

Body weight itself, which affects volume of distribution and therefore exposure at a fixed dose. Baseline body composition. Background diet and the prevalence of comorbidities. Genetic variation in drug-metabolising enzymes for compounds that depend on them. Each can shift the dose-response relationship without anything about the drug changing.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why an oral formulation raises the stakes

Oral semaglutide depends on the absorption enhancer SNAC and on strict administration conditions — a fasting window and a defined volume of water. Anything affecting gastric conditions affects absorption, and absorption of this formulation is variable to begin with. A route that fragile is more sensitive to population differences than a subcutaneous injection.

What including and excluding diabetes achieves

Recruiting participants with and without type 2 diabetes allows the same trial to describe both, and weight response has consistently been smaller in people with diabetes across this drug class. Reporting them together without separating them would produce an average describing neither group.

Why this matters for reading any headline figure

A weight-reduction percentage is a property of a trial, not of a molecule. Population, baseline weight, duration, diabetes status and estimand all move it. Two honest trials of the same drug can report meaningfully different numbers, and neither is wrong.

What it does not concern

Research material. OASIS 2 studied a licensed medicine in a defined population under clinical supervision. Nothing supplied here is semaglutide, in any formulation, or an alternative to it.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why run a separate trial in an East Asian population?: BMI thresholds for overweight and obesity are set lower in several East Asian countries because metabolic risk appears at lower BMI, so the population genuinely differs.
Why does the oral formulation make this more important?: It depends on the SNAC absorption enhancer and strict administration conditions, so it is more sensitive to anything affecting gastric conditions.
Does diabetes status change the weight result?: Yes. Weight response has consistently been smaller in people with type 2 diabetes across this drug class.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum